TriSalus Life Sciences, Inc. (TLSI) Q1 2026 Earnings Call Transcript – Image for illustrative purposes only (Image credits: Unsplash)
Westminster, Colo. – TriSalus Life Sciences released its first-quarter 2026 financial results on May 12, showing a modest revenue decline alongside a shift to net profitability and an expanded commercial team. The company, which develops drug-delivery technologies for solid-tumor treatments, reported revenue of $8.9 million for the three months ended March 31. Management used the earnings call to outline adjustments to full-year expectations while emphasizing progress on clinical data and sales infrastructure.
Quarterly Financial Snapshot
Revenue came in at $8.9 million, compared with $9.2 million in the same period a year earlier. The dip reflected temporary disruptions from territory realignment and new-hire onboarding. Gross margins improved during the quarter, and the company recorded net income of $1.5 million, a reversal from the prior-year loss. The profit was supported in part by non-operating fair-value gains on certain liabilities. A compact comparison of key line items illustrates the mixed picture:
| Metric | Q1 2026 | Q1 2025 |
|---|---|---|
| Revenue | $8.9 million | $9.2 million |
| Net Income (Loss) | $1.5 million | Loss |
Liquidity strengthened, with cash and equivalents providing a solid runway for ongoing commercial and clinical activities.
Sales-Force Buildout and Operational Focus
TriSalus more than doubled the size of its field sales organization during the quarter. The expansion is intended to accelerate adoption of the company’s Pressure-Enabled Drug Delivery (PEDD) platform, which uses pressure to improve therapeutic distribution in tumors. Executives noted that the onboarding process temporarily weighed on productivity but positioned the team for stronger execution in the second half of the year. The larger sales presence is expected to support deeper engagement with interventional oncology centers and broader reimbursement coverage. Management highlighted that early feedback from newly trained representatives has been constructive, particularly around the platform’s ability to deliver therapies more precisely.
Landmark PEDD Study and Clinical Momentum
A pivotal study of the PEDD technology demonstrated both clinical and economic advantages for patients with liver tumors. The data showed improved drug delivery efficiency and reduced procedure times, outcomes that could support broader payer acceptance. Company leaders described the results as a foundational milestone that validates the technology’s value proposition ahead of potential label expansions. These findings arrive as TriSalus continues to integrate its delivery system with standard-of-care chemotherapies and its investigational immunotherapeutic candidate. The combination approach aims to address the challenges of treating solid tumors that have historically been difficult to penetrate with conventional methods.
Updated 2026 Outlook
In light of first-quarter performance and the pace of sales-team ramp-up, TriSalus lowered its full-year revenue guidance to a range of $54 million to $57 million. The revision reflects a more measured view of commercial traction in the near term while preserving confidence in longer-term growth drivers. Analysts had previously modeled revenue near $60 million for the year. The company remains focused on achieving positive operating leverage as the expanded sales force matures and additional clinical data become available. Investors will watch for sequential revenue improvement in the coming quarters as the new representatives gain experience.
